AR108245A1 - Síntesis de indazoles - Google Patents
Síntesis de indazolesInfo
- Publication number
- AR108245A1 AR108245A1 ARP170101088A ARP170101088A AR108245A1 AR 108245 A1 AR108245 A1 AR 108245A1 AR P170101088 A ARP170101088 A AR P170101088A AR P170101088 A ARP170101088 A AR P170101088A AR 108245 A1 AR108245 A1 AR 108245A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- group
- indazoles
- synthesis
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- -1 vinyl sulfone compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicación 1: Un método para preparar un compuesto de fórmula (1), caracterizado porque comprende la siguiente etapa (A): donde un compuesto de fórmula (2) se deja reaccionar con un compuesto de vinil sulfona de fórmula (3), en la cual R representa un grupo alquilo, tal como un grupo metilo, etilo o n-propilo por ejemplo, o un grupo arilo, tal como un grupo fenilo por ejemplo, opcionalmente en un solvente de hidrocarburos aromáticos, tal como tolueno por ejemplo, preferentemente a la temperatura de reflujo de dicho solvente, proporcionando de ese modo dicho compuesto de fórmula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167652 | 2016-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108245A1 true AR108245A1 (es) | 2018-08-01 |
Family
ID=55860769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101088A AR108245A1 (es) | 2016-04-29 | 2017-04-28 | Síntesis de indazoles |
Country Status (43)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| CN109153665B (zh) | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
| JP6916207B2 (ja) | 2016-04-29 | 2021-08-11 | バイエル・ファルマ・アクティエンゲゼルシャフト | インダゾールの合成 |
| UA124103C2 (uk) * | 2016-04-29 | 2021-07-21 | Байєр Фарма Акцієнгезелльшафт | Синтез індазолів |
| MA45089A (fr) | 2016-06-01 | 2019-04-10 | Bayer Pharma AG | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes |
| AU2017272505B9 (en) * | 2016-06-01 | 2021-10-28 | Bayer Animal Health Gmbh | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| CA3104380A1 (en) | 2018-06-25 | 2020-01-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Isothiazolo[5,4-d]pyrimidine compound as irak4 inhibitor |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CN110981903A (zh) * | 2019-11-28 | 2020-04-10 | 南京正济医药研究有限公司 | 一种艾日布林中间体化合物提高光学纯度的精制方法 |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| EP4222167A1 (en) | 2020-09-30 | 2023-08-09 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| CN114469979B (zh) * | 2021-12-15 | 2024-04-09 | 安徽贝克生物制药有限公司 | 一种核糖核苷类似物的药物组合物、吸入剂及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US20100048660A1 (en) | 2006-02-10 | 2010-02-25 | Graham Michael Wynne | Treatment of duchenne muscular dystrophy |
| US7879887B2 (en) | 2006-06-29 | 2011-02-01 | Nissan Chemical Industries, Ltd. | α-amino acid derivatives and medicaments containing the same as an active ingredient |
| JP2010502717A (ja) | 2006-09-07 | 2010-01-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターロイキン１受容体関連キナーゼの調節物質 |
| EP2486925A4 (en) | 2009-10-09 | 2014-03-19 | Mitsubishi Tanabe Pharma Corp | THERAPEUTICS FOR ISCHEMIC STROKE |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| WO2012084704A1 (en) | 2010-12-20 | 2012-06-28 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| CA2929650C (en) * | 2013-11-08 | 2017-08-22 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) * | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| SG11201605408RA (en) * | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US20180289685A1 (en) * | 2015-04-30 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| EP3322698A4 (en) | 2015-07-15 | 2019-01-09 | Aurigene Discovery Technologies Limited | INDAZOL AND AZAINDAZONE COMPOUNDS AS IRAQ-4 INHIBITORS |
| CN109153665B (zh) | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
| EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| UA124103C2 (uk) * | 2016-04-29 | 2021-07-21 | Байєр Фарма Акцієнгезелльшафт | Синтез індазолів |
| JP6916207B2 (ja) | 2016-04-29 | 2021-08-11 | バイエル・ファルマ・アクティエンゲゼルシャフト | インダゾールの合成 |
| AU2017272505B9 (en) | 2016-06-01 | 2021-10-28 | Bayer Animal Health Gmbh | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| MA45089A (fr) | 2016-06-01 | 2019-04-10 | Bayer Pharma AG | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes |
-
2017
- 2017-04-25 UA UAA201811516A patent/UA124103C2/uk unknown
- 2017-04-25 MY MYPI2018703965A patent/MY190319A/en unknown
- 2017-04-25 PL PL17718558T patent/PL3448846T3/pl unknown
- 2017-04-25 EP EP17718558.4A patent/EP3448846B1/en active Active
- 2017-04-25 MY MYPI2018703968A patent/MY187184A/en unknown
- 2017-04-25 US US16/097,067 patent/US10759758B2/en active Active
- 2017-04-25 EA EA201892415A patent/EA201892415A1/ru unknown
- 2017-04-25 HR HRP20231454TT patent/HRP20231454T1/hr unknown
- 2017-04-25 LT LTEP17718558.4T patent/LT3448846T/lt unknown
- 2017-04-25 CA CA3022332A patent/CA3022332A1/en active Pending
- 2017-04-25 AU AU2017257211A patent/AU2017257211B2/en active Active
- 2017-04-25 CU CU2018000131A patent/CU20180131A7/es unknown
- 2017-04-25 AU AU2017256626A patent/AU2017256626B2/en active Active
- 2017-04-25 US US16/097,065 patent/US10501417B2/en active Active
- 2017-04-25 WO PCT/EP2017/059744 patent/WO2017186689A1/en active Application Filing
- 2017-04-25 CN CN202110343286.3A patent/CN113185457A/zh active Pending
- 2017-04-25 EP EP23189176.3A patent/EP4275754A3/en not_active Ceased
- 2017-04-25 MA MA44759A patent/MA44759B1/fr unknown
- 2017-04-25 KR KR1020187030698A patent/KR102373220B1/ko active IP Right Grant
- 2017-04-25 ES ES17718558T patent/ES2883298T3/es active Active
- 2017-04-25 TN TNP/2018/000352A patent/TN2018000352A1/en unknown
- 2017-04-25 GE GEAP201714933A patent/GEP20217214B/en unknown
- 2017-04-25 DK DK17718560.0T patent/DK3448848T3/da active
- 2017-04-25 EA EA201892430A patent/EA038035B1/ru unknown
- 2017-04-25 FI FIEP17718560.0T patent/FI3448848T3/fi active
- 2017-04-25 PT PT177185600T patent/PT3448848T/pt unknown
- 2017-04-25 SG SG11201808566WA patent/SG11201808566WA/en unknown
- 2017-04-25 CA CA3022324A patent/CA3022324A1/en active Pending
- 2017-04-25 PL PL17718560.0T patent/PL3448848T3/pl unknown
- 2017-04-25 DK DK17718558.4T patent/DK3448846T3/da active
- 2017-04-25 CN CN201780026130.4A patent/CN109071489B/zh active Active
- 2017-04-25 RS RS20231171A patent/RS64928B1/sr unknown
- 2017-04-25 EP EP23189520.2A patent/EP4275755A3/en active Pending
- 2017-04-25 LT LTEPPCT/EP2017/059767T patent/LT3448848T/lt unknown
- 2017-04-25 JP JP2018556409A patent/JP7068188B2/ja active Active
- 2017-04-25 HU HUE17718560A patent/HUE064389T2/hu unknown
- 2017-04-25 SI SI201730851T patent/SI3448846T1/sl unknown
- 2017-04-25 JP JP2018556408A patent/JP6954924B2/ja active Active
- 2017-04-25 EP EP17718560.0A patent/EP3448848B1/en active Active
- 2017-04-25 IL IL262414A patent/IL262414B2/en unknown
- 2017-04-25 RS RS20210898A patent/RS62112B1/sr unknown
- 2017-04-25 ES ES17718560T patent/ES2966772T3/es active Active
- 2017-04-25 MX MX2018013234A patent/MX2018013234A/es unknown
- 2017-04-25 SG SG11201808108XA patent/SG11201808108XA/en unknown
- 2017-04-25 MX MX2018013235A patent/MX2018013235A/es unknown
- 2017-04-25 WO PCT/EP2017/059767 patent/WO2017186703A1/en active Application Filing
- 2017-04-25 KR KR1020187030699A patent/KR102373017B1/ko active IP Right Grant
- 2017-04-25 PT PT177185584T patent/PT3448846T/pt unknown
- 2017-04-25 HU HUE17718558A patent/HUE056460T2/hu unknown
- 2017-04-25 UA UAA201811329A patent/UA123169C2/uk unknown
- 2017-04-25 CN CN201780040919.5A patent/CN109415340B/zh active Active
- 2017-04-25 BR BR112018072242-1A patent/BR112018072242A2/pt active Search and Examination
- 2017-04-25 SI SI201731443T patent/SI3448848T1/sl unknown
- 2017-04-25 PE PE2018002251A patent/PE20190107A1/es unknown
- 2017-04-27 JO JOP/2017/0100A patent/JOP20170100B1/ar active
- 2017-04-27 JO JOP/2017/0099A patent/JOP20170099B1/ar active
- 2017-04-28 TW TW106114178A patent/TWI657084B/zh active
- 2017-04-28 UY UY0001037216A patent/UY37216A/es active IP Right Grant
- 2017-04-28 AR ARP170101088A patent/AR108245A1/es unknown
- 2017-04-28 TW TW106114180A patent/TWI649314B/zh active
- 2017-04-28 UY UY0001037215A patent/UY37215A/es not_active Application Discontinuation
-
2018
- 2018-10-26 PH PH12018502289A patent/PH12018502289A1/en unknown
- 2018-10-29 EC ECSENADI201881437A patent/ECSP18081437A/es unknown
- 2018-10-29 SV SV2018005775A patent/SV2018005775A/es unknown
- 2018-10-29 CL CL2018003088A patent/CL2018003088A1/es unknown
- 2018-10-29 SA SA518400333A patent/SA518400333B1/ar unknown
- 2018-10-29 CO CONC2018/0011622A patent/CO2018011622A2/es unknown
- 2018-10-29 IL IL262659A patent/IL262659B/en active IP Right Grant
- 2018-10-29 CO CONC2018/0011644A patent/CO2018011644A2/es unknown
- 2018-10-29 DO DO2018000237A patent/DOP2018000237A/es unknown
- 2018-10-29 CL CL2018003087A patent/CL2018003087A1/es unknown
- 2018-10-29 NI NI201800112A patent/NI201800112A/es unknown
- 2018-11-28 ZA ZA2018/08057A patent/ZA201808057B/en unknown
-
2021
- 2021-07-06 HR HRP20211072TT patent/HRP20211072T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108245A1 (es) | Síntesis de indazoles | |
| CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
| CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
| RU2020113165A (ru) | Циклические пуриновые динуклеотиды в качестве модуляторов sting | |
| EA201600091A1 (ru) | 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов | |
| PE20180327A1 (es) | Proceso para preparar 4-amino-piridazinas | |
| CL2016001677A1 (es) | 5-flúor-4-imino-3-(alquil/alquilo sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona y los procesos para su preparación. | |
| AR102570A1 (es) | Síntesis de copanlisib, su sal diclorhidrato, intermediarios para su preparación e hidratos de los mismos | |
| BR112019007980A2 (pt) | método para produzir 3-alquilsulfanil-2-cloro-n-(1-alquil-1h-tetrazol-5-il)-4-trifluorometil-benzamidas | |
| AR105494A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| CY1120763T1 (el) | Νεες ενωσεις σουλφονυλαμινοβενζαμιδιου | |
| BR112019025028A2 (pt) | Método para preparar um composto. | |
| BR112015018478A2 (pt) | sistema solvente, processo para fabricação de ésteres derivados de dioxolano da fórmula i, uso do sistema solvente, uso de ésteres derivados de dioxolano da fórmula i, composição de revestimento, e, sistema ligante para fundição | |
| EA201991241A1 (ru) | Способ получения метоксиметилпиридин дикарбоксилата | |
| PH12015502851A1 (en) | Curable composition | |
| RU2017102307A (ru) | Способ получения синтетического пентапептида | |
| AR098269A1 (es) | Poliéster terminado en epoxi | |
| BR112017001569A2 (pt) | composto amida e uso do mesmo para controle de artrópodes nocivos | |
| BR112017020038A2 (pt) | método para inibir a oxidação de uma gordura insaturada. | |
| AR093787A1 (es) | Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos | |
| BR112017018503A2 (pt) | composição de cuidados pessoais, e, método. | |
| BR112017003121A2 (pt) | método para a síntese de um óxido de fosfina de hidrogênio heterocíclico | |
| BR112018008428A2 (pt) | método para sintetizar 2-alquil-4-trifluorometil-3-ácidos alquilsulfonilbenzoicos | |
| BR112018011007A2 (pt) | método para produzir 2-alquil-4-trifluorometil-3-ácidos alquil sulfonil benzoicos por oxidação de tioéter quimiosseletiva. | |
| AR108752A1 (es) | Proceso para convertir un enantiómero s en su forma racémica |